<?xml version='1.0' encoding='utf-8'?>
<document id="18636319"><sentence text="Investigation of the drug-drug interaction between alpha-lipoic acid and valproate via mitochondrial beta-oxidation."><entity charOffset="51-68" id="DDI-PubMed.18636319.s1.e0" text="alpha-lipoic acid" /><entity charOffset="73-82" id="DDI-PubMed.18636319.s1.e1" text="valproate" /><pair ddi="false" e1="DDI-PubMed.18636319.s1.e0" e2="DDI-PubMed.18636319.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18636319.s1.e0" e2="DDI-PubMed.18636319.s1.e1" /></sentence><sentence text="To investigate the potential drug-drug interaction (DDI) between lipoic acid (LA) and valproate (VA) via the mitochondrial beta-oxidation pathway in rats"><entity charOffset="65-76" id="DDI-PubMed.18636319.s2.e0" text="lipoic acid" /><entity charOffset="78-80" id="DDI-PubMed.18636319.s2.e1" text="LA" /><entity charOffset="86-95" id="DDI-PubMed.18636319.s2.e2" text="valproate" /><entity charOffset="97-99" id="DDI-PubMed.18636319.s2.e3" text="VA" /><pair ddi="false" e1="DDI-PubMed.18636319.s2.e0" e2="DDI-PubMed.18636319.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18636319.s2.e0" e2="DDI-PubMed.18636319.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18636319.s2.e0" e2="DDI-PubMed.18636319.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18636319.s2.e0" e2="DDI-PubMed.18636319.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18636319.s2.e1" e2="DDI-PubMed.18636319.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18636319.s2.e1" e2="DDI-PubMed.18636319.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18636319.s2.e1" e2="DDI-PubMed.18636319.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18636319.s2.e2" e2="DDI-PubMed.18636319.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18636319.s2.e2" e2="DDI-PubMed.18636319.s2.e3" /></sentence><sentence text="" /><sentence text="In vitro mitochondrial assays were performed to compare the biotransformation of VA to valproyl-CoA (VA-CoA), in the absence and presence of LA"><entity charOffset="101-107" id="DDI-PubMed.18636319.s4.e0" text="VA-CoA" /><entity charOffset="141-146" id="DDI-PubMed.18636319.s4.e1" text="LA" /><entity charOffset="81-86" id="DDI-PubMed.18636319.s4.e2" text="VA" /><pair ddi="false" e1="DDI-PubMed.18636319.s4.e2" e2="DDI-PubMed.18636319.s4.e2" /><pair ddi="false" e1="DDI-PubMed.18636319.s4.e2" e2="DDI-PubMed.18636319.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18636319.s4.e2" e2="DDI-PubMed.18636319.s4.e1" /><pair ddi="false" e1="DDI-PubMed.18636319.s4.e0" e2="DDI-PubMed.18636319.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18636319.s4.e0" e2="DDI-PubMed.18636319.s4.e1" /></sentence><sentence text=" In vitro microsomal and protein binding assays were performed to elucidate their potential DDI at the microsomal metabolism and distribution levels" /><sentence text=" A pharmacokinetic study was conducted in Lister Hooded rats to ascertain the in vivo DDI between LA and VA"><entity charOffset="98-99" id="DDI-PubMed.18636319.s6.e0" text="LA" /><entity charOffset="105-106" id="DDI-PubMed.18636319.s6.e1" text="VA" /><pair ddi="false" e1="DDI-PubMed.18636319.s6.e0" e2="DDI-PubMed.18636319.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18636319.s6.e0" e2="DDI-PubMed.18636319.s6.e1" /></sentence><sentence text="" /><sentence text="LA was shown to decrease significantly (p &lt; 0"><entity charOffset="0-1" id="DDI-PubMed.18636319.s8.e0" text="LA" /></sentence><sentence text="05) the in vitro formation of VA-CoA in a concentration-dependent manner"><entity charOffset="30-31" id="DDI-PubMed.18636319.s9.e0" text="VA" /></sentence><sentence text=" Our in vitro assay results confirmed that there was minimal interaction between LA and VA in microsomal metabolism and protein binding"><entity charOffset="81-82" id="DDI-PubMed.18636319.s10.e0" text="LA" /><entity charOffset="88-89" id="DDI-PubMed.18636319.s10.e1" text="VA" /><pair ddi="false" e1="DDI-PubMed.18636319.s10.e0" e2="DDI-PubMed.18636319.s10.e0" /><pair ddi="false" e1="DDI-PubMed.18636319.s10.e0" e2="DDI-PubMed.18636319.s10.e1" /></sentence><sentence text=" Based on the pharmacokinetic data, the absolute bioavailability of VA was determined to be 1"><entity charOffset="68-69" id="DDI-PubMed.18636319.s11.e0" text="VA" /></sentence><sentence text="3 in the presence of LA"><entity charOffset="21-22" id="DDI-PubMed.18636319.s12.e0" text="LA" /></sentence><sentence text="" /><sentence text="Our study demonstrated for the first time that there is a potential DDI between LA and VA at the mitochondrial beta-oxidation level"><entity charOffset="80-81" id="DDI-PubMed.18636319.s14.e0" text="LA" /><entity charOffset="87-88" id="DDI-PubMed.18636319.s14.e1" text="VA" /><pair ddi="false" e1="DDI-PubMed.18636319.s14.e0" e2="DDI-PubMed.18636319.s14.e0" /><pair ddi="false" e1="DDI-PubMed.18636319.s14.e0" e2="DDI-PubMed.18636319.s14.e1" /></sentence><sentence text=" While further clinical study is essential, our preliminary finding suggested that medical practitioners need to be prudent when managing epileptic patients who are co-administered with both VA and LA"><entity charOffset="198-199" id="DDI-PubMed.18636319.s15.e0" text="LA" /><entity charOffset="191-192" id="DDI-PubMed.18636319.s15.e1" text="VA" /><pair ddi="false" e1="DDI-PubMed.18636319.s15.e1" e2="DDI-PubMed.18636319.s15.e1" /><pair ddi="false" e1="DDI-PubMed.18636319.s15.e1" e2="DDI-PubMed.18636319.s15.e0" /></sentence><sentence text="" /></document>